New strategies for cancer gene therapy: Progress and opportunities

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 1, 2010, Pages 108-114

  Cao, Siyu ^a   Cripps, Allan ^a   Wei, Ming Q ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Anaerobic bacteria; Angiogenesis; Cancer gene therapy; Gene delivery; Solid tumour; Therapeutic gene

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL VECTOR; INTERLEUKIN 12; INTERLEUKIN 7; LIPOSOME; PARVOVIRUS VECTOR; POLYMER; RECOMBINANT DNA; RETROVIRUS VECTOR; VIRUS VECTOR;

ADENOVIRUS; ANAEROBIC BACTERIUM; ANTIANGIOGENIC ACTIVITY; BIFIDOBACTERIUM; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CHEMOSENSITIZATION; CHEMOTHERAPY; CLOSTRIDIA; CONFERENCE PAPER; DENDRITIC CELL; GENE DELIVERY SYSTEM; GENE VECTOR; HERPES SIMPLEX VIRUS; HYPOXIA; IMMUNOMODULATION; IMMUNOTHERAPY; METASTASIS; NONHUMAN; ONCOGENE; ONCOLYTIC VIROTHERAPY; PATHOPHYSIOLOGY; POXVIRUS; RADIOSENSITIZATION; SALMONELLA; SOLID TUMOR; SUICIDE GENE THERAPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE;

BACTERIA, ANAEROBIC; COMBINED MODALITY THERAPY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; VIRUSES;

EID: 74049091788     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05268.x     Document Type: Conference Paper

References (56)

1. Rochlitz CF. Gene therapy of cancer. Swiss Med. Wkly. 2001 131 : 4 9.
2. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000 288 : 669 672. (Pubitemid 30241569)
3. Kopnin BP. Targets of oncogenes and tumor suppressors: Key for understanding basic mechanisms of carcinogenesis. Biochemistry 2000 65 : 2 27.
4. Kashani-Sabet M, Funato T, Tone T et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. Dev. 1992 2 : 3 15.
5. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 1993 53 : 1743 1746.
6. Rosenberg SA. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 2004 350 : 1461 1463.
7. Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Semin. Oncol. 2007 34 : 524 531.
8. Sportes C, Gress RE. Interleukin-7 immunotherapy. Adv. Exp. Med. Biol. 2007 601 : 321 333.
9. Brown JM, Giaccia AJ. The unique physiology of solid tumors. Opportunities (and problems) for cancer therapy. Cancer Res. 1998 58 : 1408 1416.
10. Wei MQ, Mengesha A, Good D, Anne J. Bacterial targeted tumour therapy: Dawn of a new era. Cancer Lett. 2008 259 : 16 27.
11. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003 22 : 7486 7495.
12. Buchschacher GL Jr. Introduction to retroviruses and retroviral vectors. Somat. Cell Mol. Genet. 2001 26 : 1 11.
13. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol. Ther. 1998 80 : 35 47.
14. Tai CK, Kasahara N. Replication-competent retrovirus vectors for cancer gene therapy. Front. Biosci. 2008 13 : 3083 3095.
15. Gilbert JR, Wong-Staal F. HIV-2 and SIV vector systems. Somat. Cell Mol. Genet. 2001 26 : 83 98.
16. McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum. Gene Ther. 2004 15 : 1022 1033.
17. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 1995 69 : 2004 2015.
18. Marconi P, Krisky D, Oligino T et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc. Natl Acad. Sci. USA 1996 93 : 11319 11320.
19. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965 149 : 754 756.
20. Liu Y, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood 2006 107 : 3027 3033.
21. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett. 2007 254 : 178 216.
22. Kaneda Y, Tabata Y. Non-viral vectors for cancer therapy. Cancer Sci. 2006 97 : 348 354.
23. Wang MD, Shin DM, Simons JW, Nie S. Nanotechnology for targeted cancer therapy. Expert Rev. Anticancer Ther. 2007 7 : 833 837.
24. Zhou J, Schmid T, Schnitzer S, Brune B. Tumor hypoxia and cancer progression. Cancer Lett. 2006 237 : 10 21.
25. Kimura NT, Taniguchi S, Aoki K, Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 1980 40 : 2061 2068.
26. Wang L, Pan L, Shi L, Sun Y, Zhang Y, Zhou D. Roles of bifidobacterium on prevention of experimental colorectal carcinoma and induction of apoptosis. Zhonghua Yu Fang Yi Xue Za Zhi 1999 33 : 337 339 in Chinese).
27. Hou X, Liu JE. Construction of Escherichia coli-Bifidobacterium longum shuttle vector and expression of tumor suppressor gene PTEN in B. longum. Wei Sheng Wu Xue Bao 2006 46 : 347 352 in Chinese).
28. Hidaka A, Hamaji Y, Sasaki T, Taniguchi S, Fujimori M. Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy. Biosci. Biotechnol. Biochem. 2007 71 : 2921 2926.
29. Xu YF, Zhu LP, Hu B et al. A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther. 2007 14 : 151 157.
30. Li X, Fu GF, Fan YR et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 2003 10 : 105 111.
31. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997 57 : 4537 4544.
32. Friedlos F, Lehouritis P, Ogilvie L et al. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin. Cancer Res. 2008 14 : 4259 4266.
33. Feltis BA, Miller JS, Sahar DA et al. Liver and circulating NK1.1(+) CD3(-) cells are increased in infection with attenuated Salmonella typhimurium and are associated with reduced tumor in murine liver cancer. J. Surg. Res. 2002 107 : 101 107.
34. Barnett SJ, Soto LJ 3rd., Sorenson BS, Nelson BW, Leonard AS, Saltzman DA. Attenuated Salmonella typhimurium invades and decreases tumor burden in neuroblastoma. J. Pediatr. Surg. 2005 40 : 993 997.
35. al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, Al-Salam S, Bashir G, Chouaib S. Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin. Immunol. 2009 130 : 89 97.
36. Yoon WS, Choi WC, Sin JI, Park YK. Antitumor therapeutic effects of Salmonella typhimurium containing Flt3 ligand expression plasmids in melanoma-bearing mouse. Biotechnol. Lett. 2007 29 : 511 516.
37. Lee CH, Wu CL, Shiau AL. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J. Gene Med. 2004 6 : 1382 1393.
38. Lee CH, Wu CL, Tai YS, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol. Ther. 2005 11 : 707 716.
39. Zhao M, Yang M, Li XM et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc. Natl Acad. Sci. USA 2005 102 : 755 760. (Pubitemid 40282738)
40. Cunningham C, Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum. Gene Ther. 2001 12 : 1594 1596.
41. Nemunaitis J, Cunningham C, Senzer N et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003 10 : 737 744.
42. Parker RC, Plummer HC, Siebenmann CO, Chapman MG. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc. Soc. Exp. Biol. Med. 1947 66 : 461 467.
43. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl Acad. Sci. USA 2001 98 : 15.
44. Dang LH, Bettegowda C, Agrawal N et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol. Ther. 2004 3 : 326 337.
45. Barbe S, Van Mellaert L, Theys J et al. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol. Lett. 2005 246 : 67 73.
46. Theys J, Nuyts S, Landuyt W et al. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. Appl. Environ. Microbiol. 1999 65 : 4295 4300.
47. Lemmon MJ, van Zijl P, Fox ME et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997 4 : 791 796.
48. Groot AJ, Mengesha A, van der Wall E, van Diest PJ, Theys J, Vooijs M. Functional antibodies produced by oncolytic clostridia. Biochem. Biophys. Res. Commun. 2007 364 : 985 989.
49. Hodish I, Tal R, Shaish A et al. Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK. Cancer Biol. Ther. 2009 8 : 424 432.
50. Liao Y, Zou YY, Xia WY, Hung MC. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Ther. 2004 11 : 594 602.
51. Fu W, Chu L, Han X, Liu X, Ren D. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models. J. Gene Med. 2008 10 : 690 701.
52. Fang B, Roth JA. Tumor-suppressing gene therapy. Cancer Biol. Ther. 2003 2 (Suppl. 1 S115 21.
53. Seth P. Vector-mediated cancer gene therapy: An overview. Cancer Biol. Ther. 2005 4 : 512 517.
54. Colletier PJ, Ashoori F, Cowen D et al. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int. J. Radiat. Oncol. Biol. Phys. 2000 48 : 1507 1512.
55. Mauceri HJ, Beckett MA, Liang H et al. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 16 : 373 381.
56. Tomioka A, Tanaka M, De Velasco MA et al. Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol. Cancer Ther. 2008 7 : 1864 1870.